Get started
Author

Maciej Rotarski

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
2015 · M. Schuler, J.C.-H. Yang, et al. · Annals of Oncology · 132
PDF
Home parenteral nutrition improves quality of life and nutritional status in patients with cancer: a French observational multicentre study
2014 · S. Culine, C. Chambrier, et al. · Supportive Care in Cancer · 70
A Prospective Observational Study Assessing Home Parenteral Nutrition in Patients With Gastrointestinal Cancer: Benefits for Quality of Life
2014 · Pierre Senesse, Abir Tadmouri, et al. · Journal of Pain and Symptom Management · 39
PDF
Nutrition parentérale à domicile chez la personne âgée atteinte d’un cancer : une étude observationnelle prospective
2014 · Patrick Seys, Abir Tadmouri, et al. · Bulletin du Cancer · 16
853MO Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial
2024 · J. Fayette, G. Thomas, et al. · Annals of Oncology · 13
PDF
Granocyte-colony stimulating factor (G-CSF) has significant efficacy as secondary prophylaxis of chemotherapy-induced neutropenia in patients with solid tumors: results of a prospective study.
2013 · Gilles Freyer, Nicolas Jovenin, et al. · PubMed · 10
Observational, prospective, phase 4 study in patients with first‐line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum‐based therapy: DIRECT
2021 · Joël Guigay, Emmanuel Chamorey, et al. · Cancer Reports · 9
PDF
Epoetin beta in patients with metastatic breast cancer receiving chemotherapy: Results from the Breast Cancer - Anemia and the Value of Erythropoietin (BRAVE) study
2005 · M. Marangolo, N. Malamos, et al. · Journal of Clinical Oncology · 3
Prise en charge des cancers bronchiques non à petites cellules après docétaxel-cisplatine
2007 · J.L. Breton, G. Robinet, et al. · Revue des Maladies Respiratoires · 2
695P Effectiveness and quality-of-life (QoL) data from real-world study (ProNiHN) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with nivolumab (nivo) in France
2022 · C. Le Tourneau, S. Salas, et al. · Annals of Oncology · 1
French experience of patient management when receiving oral vinorelbine chemotherapy (NVBO) for metastatic breast cancer: Final results of a prospective observational survey on practices
2009 · J. Lotz, F. Husseini, et al. · Journal of Clinical Oncology · 1
Supplementary Figure S5 from Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study
2026 · Jérôme Fayette, Gareth J. Thomas, et al.
Supplementary Figure S1 from Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study
2026 · Jérôme Fayette, Gareth J. Thomas, et al.
Supplementary Table S6 from Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study
2026 · Jérôme Fayette, Gareth J. Thomas, et al.
Supplementary Figure S2 from Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study
2026 · Jérôme Fayette, Gareth J. Thomas, et al.
Supplementary Table S3 from Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study
2026 · Jérôme Fayette, Gareth J. Thomas, et al.
Supplementary Table S4 from Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study
2026 · Jérôme Fayette, Gareth J. Thomas, et al.
Table 1 from Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study
2026 · Jérôme Fayette, Gareth J. Thomas, et al.
Supplementary Figure S4 from Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study
2026 · Jérôme Fayette, Gareth J. Thomas, et al.
Supplementary Table S1 from Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study
2026 · Jérôme Fayette, Gareth J. Thomas, et al.
Supplementary Table S6 from Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study
2026 · Jérôme Fayette, Gareth J. Thomas, et al.
Supplementary Table S5 from Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study
2026 · Jérôme Fayette, Gareth J. Thomas, et al.
Supplementary Table S2 from Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study
2026 · Jérôme Fayette, Gareth J. Thomas, et al.
Supplementary Table S5 from Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study
2026 · Jérôme Fayette, Gareth J. Thomas, et al.
Supplementary Figure S5 from Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study
2026 · Jérôme Fayette, Gareth J. Thomas, et al.
Works count: 41
Citation count: 296
H-index: 7
I10-index: 6
Year
Topic
Type